New hope for HAE patients: long-term navenibart trial expands

NCT ID NCT07204938

ENROLLING_BY_INVITATION Disease control Sponsor: Astria Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 27 times

Summary

This study tests the long-term safety and effectiveness of a drug called navenibart for people with hereditary angioedema (HAE), a condition that causes sudden, painful swelling. It is open to adults and teens who were in a previous navenibart study. Participants will receive navenibart, and some may later get a personalized dose based on their needs. The goal is to see if the drug keeps working safely over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA (HAE) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Site 1

Walnut Creek, California, 94598, United States
Site 10

Hong Kong, Hong Kong
Site 2

Scottsdale, Arizona, 85251, United States
Site 3

Little Rock, Arkansas, 72205, United States
Site 4

Santa Monica, California, 90404, United States
Site 5

Centennial, Colorado, 80112, United States
Site 6

Cincinnati, Ohio, 45236, United States
Site 7

San Diego, California, 92122, United States
Site 8

Cambridge, United Kingdom
Site 9

Hershey, Pennsylvania, 17033, United States

Conditions

Explore the condition pages connected to this study.

HEREDITARY ANGIOEDEMA (HAE)